Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.53 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.52 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28899309 | 0.89 | NPC1 (0.58) | SMN1; SMN2EPHX2NPC1RAB9AALDH1A1 | |
| SCHEMBL30938277 | 0.88 | SMN1; SMN2 (0.54) | AKR1C3AKR1C2KCNK2SMN1; SMN2EPHX2 | |
| SCHEMBL3394380 | 0.88 | ALDH1A1 (0.59) | SMN1; SMN2EPHX2NPC1RAB9AKDM4E | |
| SCHEMBL23140494 | 0.88 | SMN1; SMN2 (0.54) | AKR1C3AKR1C2KCNK2SMN1; SMN2EPHX2 | |
| SCHEMBL5460005 | 0.86 | MAPK10 (0.53) | EPHX2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL22979384 | 0.86 | KDM4E (0.51) | AKR1C3AKR1C2EPHX2NPC1RAB9A | |
| SCHEMBL5729973 | 0.86 | EPHX2 (0.48) | AKR1C3AKR1C2SMN1; SMN2EPHX2NPC1 | |
| SCHEMBL26020311 | 0.85 | EPHX2 (0.47) | AKR1C3AKR1C2SMN1; SMN2EPHX2NPC1 | |
| SCHEMBL10222517 | 0.84 | AKR1C3 (0.56) | AKR1C3AKR1C2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL19230564 | 0.83 | MAPT (0.48) | SMN1; SMN2EPHX2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| JP-3135943-A | — | — | None | — | — | JP | disclosed |
| CN-118792060-A | Ferroelectric nematic liquid crystal molecule, preparation method and application thereof | 南京材化电子新材料有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20180362485-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-12-20 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| EP-3319961-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP1, TLL1 AND/OR TLL2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-05-16 | — | — | EP | disclosed |
| EP-2804868-B1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2010034982-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. (SG) | 2010-04-01 | — | — | WO | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0423991-B1 | Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid | SHOWA SHELL SEKIYU (JP) | 1995-06-14 | — | — | EP | disclosed |
| US-5183934-A | 2-trifluoromethyl-4-hydroxybenzoic acid | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1993-02-02 | — | — | US | disclosed |
| JP-H03135943-A | 2-TRIFLUOROMETHYL-4-HYDROXYBENZOIC ACID | SHOWA SHELL SEKIYU KK | 1991-06-10 | — | — | JP | disclosed |
| EP-0423991-A2 | Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | AKR1C3 535/4885AKR1C2 727/4885KCNK2 3027/4885 |
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | AKR1C3 317/4885AKR1C2 278/4885KCNK2 1182/4885 |
| US-20180362485-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS | BMP1, BMP2, BMPR1A | AKR1C3 3792/4885AKR1C2 3290/4885KCNK2 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.